Joe Kim's questions to AWH leadership • Q1 2024
Question
Asked about the recommended frequency for Longitudinal Monitoring with OvaWatch, any reimbursement limits on testing frequency, the marketing strategy for the new publications, and the current landscape for endometriosis diagnosis, including the overlap with their current sales efforts.
Answer
The company stated that the frequency of OvaWatch repeat testing is left to physician discretion, with no current reimbursement limits. The new publications are being actively marketed through the sales force, inside sales, and KOL events. Regarding endometriosis, the diagnostic landscape still relies on invasive surgery, and there is a significant overlap in the target physician audience with OvaSuite, along with strong, pre-existing patient demand for better diagnostics.